1-硬脂酰基-2-亚油酰基-sn-甘油-3-磷酸乙醇胺 | 7266-53-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 1-硬脂酰基-2-亚油酰基-sn-甘油-3-磷酸乙醇胺
• 英文名称: 2-azaniumylethyl (2R)-2-{[(9Z,12Z)-octadeca-9,12-dienoyl]oxy}-3-(octadecanoyloxy)propyl phosphate
• 英文别名: 2-azaniumylethyl [(2R)-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-octadecanoyloxypropyl] phosphate
• CAS: 7266-53-7
• 化学式: C41H78NO8P
• 分子量: 744.0
• InChiKey: YDTWOEYVDRKKCR-KNERPIHHSA-N

物化性质

• 沸点：
  759.2±70.0 °C(Predicted)
• 密度：
  1.008±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  10.8
• 重原子数：
  51
• 可旋转键数：
  41
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

安全信息

• WGK Germany：
  3

文献信息

• [EN] siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS<br/>[FR] ARNSI POSSÉDANT AU MOINS DEUX LIGANDS À DEUX EXTRÉMITÉS DISTINCTES
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：WO2019193189A1

  公开（公告）日：2019-10-10

  There is provided inter alia a conjugate for inhibiting expression of a target gene in a cell, said conjugate comprising a nucleic acid portion and ligand portions, said nucleic acid portion comprising at least one duplex region that comprises at least a portion of a first RNA strand and at least a portion of a second RNA strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene, said ligand portions comprising a linker moiety and a targeting ligand for in vivo targeting of cells and being conjugated exclusively to the 3' and/or 5' ends of one or both RNA strands, wherein the 5' end of the first RNA strand is not conjugated, wherein: (i) the second RNA strand is conjugated at the 5' end to the targeting ligand, and wherein (a) the second RNA strand is also conjugated at the 3' end to the targeting ligand and the 3' end of the first RNA strand is not conjugated; or (b) the first RNA strand is conjugated at the 3' end to the targeting ligand and the 3' end of the second RNA strand is not conjugated; or (c) both the second RNA strand and the first RNA strand are also conjugated at the 3' ends to the targeting ligand; or (ii) both the second RNA strand and the first RNA strand are conjugated at the 3' ends to the targeting ligand and the 5' end of the second RNA strand is not conjugated.

  提供了一种用于抑制细胞中靶基因表达的共轭物，该共轭物包括核酸部分和配体部分，所述核酸部分包括至少一个双链区域，该区域包括至少部分第一RNA链和至少部分第二RNA链，该第二RNA链至少部分与第一链互补，其中所述第一链至少部分与从所述靶基因转录的RNA的至少部分互补，所述配体部分包括连接子基团和用于体内细胞靶向的靶向配体，并且仅连接到一个或两个RNA链的3'和/或5'末端，其中第一RNA链的5'末端未连接，其中：(i) 第二RNA链在5'末端连接到靶向配体，其中(a) 第二RNA链还在3'末端连接到靶向配体，且第一RNA链的3'末端未连接；或(b) 第一RNA链在3'末端连接到靶向配体，且第二RNA链的3'末端未连接；或(c) 第二RNA链和第一RNA链的3'末端均连接到靶向配体；或(ii) 第二RNA链和第一RNA链的3'末端均连接到靶向配体，且第二RNA链的5'末端未连接。
• [EN] NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL<br/>[FR] ACIDES NUCLÉIQUES POUR INHIBER L'EXPRESSION DE PROS1 DANS UNE CELLULE
  申请人：UNIV BERN

  公开号：WO2020225301A1

  公开（公告）日：2020-11-12

  The invention relates to nucleic acid products that interfere with PROS1 gene expression or inhibit its expression. The nucleic acids are particularly for use in the treatment, prevention or reduction of risk of suffering from a bleeding disorder.

  该发明涉及干扰PROS1基因表达或抑制其表达的核酸产品。这些核酸特别用于治疗、预防或减少患出血障碍的风险。
• [EN] NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL<br/>[FR] ACIDES NUCLÉIQUES POUR INHIBER L'EXPRESSION DE CNNM4 DANS UNE CELLULE
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：WO2021239825A1

  公开（公告）日：2021-12-02

  The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.

  本发明涉及与干扰或抑制CNNM4（Cyclin M4）基因表达有关的核酸产品。它进一步涉及使用CNNM4抑制剂治疗疾病，例如肝病，包括非酒精性脂肪性肝病（NAFLD），非酒精性脂肪性肝炎（NASH），肝脂肪变性，肝纤维化，肝硬化，肝癌和其他与镁离子调节失调有关的疾病。
• Novel neutral (bio)material
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：EP2444464A1

  公开（公告）日：2012-04-25

  The instant invention concerns - a method for preparing a material comprising the following steps of a) treating the support to obtain a layer having SiH function, b) grafting the SiH layer obtained in step a) with an alkene and a catalyst for covalently bonding the alkene to the coating, said alkene being non-terminal and/or having an hydrophilic part, and c) recovering a material comprising a support coated with a chain covalently grafted with Si-C bonds, - a material comprising a support, optionally comprising a polyhydrosiloxane layer, on which surface is covalently bonded a grafted chain, wherein the covalent bonding between the support and/or the polyhydrosiloxane and the chain is an Si-C bond, and the grafted chain is bonded through a non-terminal carbon, through more than one covalent bond and/or the chain is having at least one hydrophilic part, and - devices comprising such material.

  本发明涉及 - 一种制备材料的方法，包括以下步骤 a) 处理支持物以获得具有 SiH 功能的层；b) 将步骤 a) 中获得的 SiH 层与烯烃和催化剂接枝，以将烯烃共价键合到涂层上，所述烯烃为非末端烯烃和/或具有亲水部分；以及 c) 回收一种材料，该材料包括涂有共价键合的 Si-C 键接枝链的支持物、 - 一种材料，包括支撑体，可选择包括聚氢硅氧烷层，在支撑体表面共价键合了一条接枝链，其中支撑体和/或聚氢硅氧烷与链之间的共价键合是 Si-C 键，接枝链通过非末端碳键、通过一个以上的共价键和/或链具有至少一个亲水部分键合，以及 - 包括这种材料的装置。
• LIPID NANOPARTICLE FORMULATION
  申请人：Silence Therapeutics (London) Ltd

  公开号：EP3315125A1

  公开（公告）日：2018-05-02

  The present invention relates to formulations comprising cationic lipids, including novel cationic lipids, in combination with other lipid components such as cholesterol, fusogenic co-lipids, and PEG-lipids to form lipid nanoparticles with nucleotides to facilitate cellular uptake.

  本发明涉及由阳离子脂质（包括新型阳离子脂质）与其他脂质成分（如胆固醇、融合性助脂质和 PEG 脂质）组合而成的制剂，以形成带有核苷酸的脂质纳米颗粒，从而促进细胞吸收。